Scaffold Therapeutics develops RNA-targeted cancer therapies using machine learning to analyze and regulate RNA modifications that affect stability, transcription, and degradation. Their platform accelerates drug discovery across oncology and neurodegenerative diseases by providing insights into pathway biology and aligning experimental research with clinical objectives.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery processes for cancer and neurodegenerative diseases are slow and inefficient, often failing to fully leverage the complexities of RNA biology. Understanding and manipulating RNA modifications, which influence stability, transcription, and degradation, remains a significant challenge in developing effective therapies.
Solution
Scaffold Therapeutics has developed a drug discovery platform that uses machine learning to analyze and regulate RNA modifications, enabling the development of RNA-targeted therapies for oncology and neurodegenerative diseases. The platform provides insights into pathway biology and aligns experimental research with clinical objectives, accelerating the identification of promising drug candidates. By focusing on RNA modifications that control stability, transcription, and degradation, Scaffold Therapeutics aims to create a pipeline of assets targeting clinically validated and first-in-class biology. The platform helps to overcome the limitations of traditional methods by providing a more comprehensive understanding of the transcriptome.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and neurodegenerative diseases.
Features
- Machine learning-driven analysis of RNA modifications
- Identification of novel drug targets in oncology and neurodegenerative diseases
- Regulation of RNA stability, transcription, and degradation
- Platform designed to accelerate drug discovery
- Focus on clinically validated and first-in-class biology